some bodies must be really sensitive, and that sensitivity could translate into a better response hairwise...
for the record,
in theory ODM is more potent than ORM...
View attachment 157356
but in practise, this may not have any value, as ARN's therapeutic effectiveness is not predicted in these graphs...
Apalutamide is molecularly and mechanistically similar to enzalutamide, as it antagonizes the ligandbinding domain of androgen receptor (AR) with potent affinity, thereby preventing AR nuclear translocation; it also does not have agonistic effects in the presence of AR overexpression [27]. Apalutamide led to ≥ 50% tumor regression in eight of ten castrate immunodeficient mice harboring LNCaP/AR xenograft tumors, whereas bicalutamide led to ≥ 50% tumor regression in only one of the ten evaluated mice [27]. Notably, apalutamide also demonstrated greater in vivo activity in CRPC xenograft models [28], compared to enzalutamide, 2–4-times lower doses of apalutamide were needed to achieve stable, therapeutic plasma concentrations in a mouse model of human CRPC xenografts with approximately the same drug concentrations in the tumor; this suggests a higher therapeutic index for apalutamide with a greater scope for dose escalation [27].
@Avacado your response to ORM will be interesting, i'd still recommend having your preferred SERM on hand...